Informationen:
Fehler:
ID
34754
Beschreibung
Vildagliptin Veresus Liraglutide - Patient Preference After Receiving Both Medications; ODM derived from: https://clinicaltrials.gov/show/NCT01518101
Link
https://clinicaltrials.gov/show/NCT01518101
Stichworte
Versionen (1)
- 26.01.19 26.01.19 -
Rechteinhaber
See clinicaltrials.gov
Hochgeladen am
26. Januar 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Type 2 Diabetes NCT01518101
Eligibility Type 2 Diabetes NCT01518101
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Type 2 Diabetes NCT01518101
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Diabetes Mellitus, Non-Insulin-Dependent
Item
patients with type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
Metformin
Item
metformin monotherapy > 12 weeks
boolean
C0025598 (UMLS CUI [1])
Hemoglobin A1c measurement
Item
hemoglobin a1c (hba1c) > 6.5 % and < 9.0 %
boolean
C0474680 (UMLS CUI [1])
Body mass index
Item
body mass index (bmi) 19-35 (kg/m²)
boolean
C1305855 (UMLS CUI [1])
Acute Disease
Item
acute diseases at randomization
boolean
C0001314 (UMLS CUI [1])
Kidney Diseases | Creatinine measurement, serum | Glomerular Filtration Rate
Item
kidney diseases with creatinin > 120 µmol/l, glomerular filtration rate (gfr) <50 ml/min
boolean
C0022658 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
C0017654 (UMLS CUI [3])
C0201976 (UMLS CUI [2])
C0017654 (UMLS CUI [3])
Medical contraindication Gliptins | Medical contraindication Glucagon-Like Peptide Analogue
Item
contraindication for gliptins or glucagon-like-peptide-analogues according to the respective summary of product characteristics (smpc)
boolean
C1301624 (UMLS CUI [1,1])
C1827106 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0014361 (UMLS CUI [2,2])
C0243071 (UMLS CUI [2,3])
C1827106 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0014361 (UMLS CUI [2,2])
C0243071 (UMLS CUI [2,3])
Dipeptidyl-Peptidase IV Inhibitors | GLP-1 Mimetics
Item
previous use of dipeptidyl peptidase-4-inhibitors and glp-1-mimetics
boolean
C1827106 (UMLS CUI [1])
C3273809 (UMLS CUI [2])
C3273809 (UMLS CUI [2])
Eligibility Criteria Study Protocol
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
C2348563 (UMLS CUI [1,2])